A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Phase I First-in-Human, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Tingbo Liang
- Número de teléfono: +86 13666676121
- Correo electrónico: liangtingbo_trial@163.com
Copia de seguridad de contactos de estudio
- Nombre: Xueli Bai
- Correo electrónico: baixueli_trial@163.com
Ubicaciones de estudio
-
-
Fujian
-
Fuzhou, Fujian, Porcelana, 350014
- Reclutamiento
- Fujian Cancer Hospital
-
Contacto:
- Zengqing Guo
-
-
Henan
-
Zhengzhou, Henan, Porcelana, 450000
- Aún no reclutando
- The First Affiliated Hospital of Zhengzhou University
-
Contacto:
- Shuiling Jin
-
-
Hunan
-
Changsha, Hunan, Porcelana, 410013
- Aún no reclutando
- Hunan Cancer Hospital
-
Contacto:
- Haiyan Yang
-
Contacto:
- Xingxiang Pu
-
-
Liaoning
-
Shenyang, Liaoning, Porcelana, 110000
- Aún no reclutando
- The First Hospital of China Medical University
-
Contacto:
- Yunpeng Liu
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250117
- Aún no reclutando
- Cancer Hospital of Shandong First Medical University
-
Contacto:
- Shuqin Ni
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310003
- Reclutamiento
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contacto:
- Tingbo Liang
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- In dose-escalation cohorts (Part 1), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- In the dose-expansion cohorts (Part 2), histologically or cytologically confirmed selected advanced solid tumors.
- Subjects must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.
- Life expectancy ≥12 weeks.
- Patients of childbearing potential (male and female) must agree to use reliable methods of contraception until at least 180 days after the last dose.
Exclusion Criteria:
- Symptomatic brain metastases.
- Serious non-healing wounds, ulcers or fractures.
- Toxicity from previous treatment has to restore to ≤ grade 1.
- Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to enrollment.
- Use of aspirin (> 325 mg/day) within 6 months prior to the first dose.
- Active hepatitis B or hepatitis C.
- Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- Known hereditary or acquired predisposition to bleeding and thrombosis.
- History of gastrointestinal perforation, gastrointestinal bleeding, fistula, or any life-threatening bleeding event within 6 months prior to enrollment.
- Prior permanent discontinuation of PD-(L)1 and/or VEGF monoclonal antibody because of immune/anti-angiogenesis toxicities, or history of Grade ≥3 immune/anti-angiogenesis-related AEs
- Known or suspected active autoimmune disease.
- Patients with proteinuria at screening (Urine protein >2+ at screening, or 2+ urine protein accompanied by 24-h urine protein ≥1 g/24 h).
- History of myocardial infarction or stroke within 6 months prior to enrollment.
- Subjects with clinically significant cardiovascular disease within 6 months prior to the first dose.
- Pregnant and lactating women.
- Known allergies to any excipient in the study drug.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: SIM0689 for Injection
One intravenous infusion of SIM0689 for Injection, 28 days or 21 days as a treatment cycle.
|
SIM0689 for Injection is a Programmed Cell Death Protein 1(PD1) / Vascular Endothelial Growth Factor (VEGF) bispecific antibody.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dose-limiting toxicity (DLT) (Dose escalation)
Periodo de tiempo: at the end of Cycle 1 (each cycle is 28 days)
|
DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria.
|
at the end of Cycle 1 (each cycle is 28 days)
|
|
Maximum tolerated dose (MTD)and / or Recommended dose (RD) (Dose escalation)
Periodo de tiempo: Up to approximately 2 years
|
The MTD is defined as the dose of SIM0689 with an estimated toxicity rate closest to the target toxicity rate of 27%; RD stands for Recommended Dose, which will be selected based on the evaluation of all available pharmacokinetics, pharmacodynamic, efficacy, safety, and tolerability data |
Up to approximately 2 years
|
|
Objective Response Rate (ORR) (Dose expansion)
Periodo de tiempo: Up to approximately 2 years
|
ORR is the proportion of participants with complete response(CR)or partial response (PR) assessed according to RECIST v1.1.
|
Up to approximately 2 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse event rate
Periodo de tiempo: up to approximately 2 years
|
The occurrence of all adverse events (AEs), evaluated by Common Terminology Criteria for Adverse Events (CTCAE) 6.0.
|
up to approximately 2 years
|
|
Pharmacokinetics: The area under the curve (AUC)
Periodo de tiempo: up to approximately 2 years
|
The area under the curve (AUC) of serum concentration of SIM0689
|
up to approximately 2 years
|
|
Pharmacokinetics: Peak concentration (Cmax)
Periodo de tiempo: Up to approximately 2 years
|
Maximum observed concentration (Cmax) of SIM0689
|
Up to approximately 2 years
|
|
Pharmacokinetics: T1/2
Periodo de tiempo: Up to approximately 2 years
|
Terminal half-life (T1/2)
|
Up to approximately 2 years
|
|
Pharmacokinetics: Tmax
Periodo de tiempo: Up to approximately 2 years
|
Time to maximum concentration
|
Up to approximately 2 years
|
|
Immunogenicity
Periodo de tiempo: Up to approximately 2 years
|
Titer of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
|
Immunogenicity
Periodo de tiempo: Up to approximately 2 years
|
Incidence rate of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
|
Immunogenicity
Periodo de tiempo: Up to approximately 2 years
|
Duration of serum anti-SIM0689 antibodies
|
Up to approximately 2 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- SIM0689-101
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .